BS_QT3NZ2YZ
Embryonal tumors
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Embryonal tumors
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Embryonal tumors
- overall_survival_months
- 37.417871222076215
- age_years
- 1.997
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.643
- MYC_TARGETS_V2+0.563
- G2M_CHECKPOINT+0.541
- MYC_TARGETS_V1+0.502
- PANCREAS_BETA_CELLS+0.391
- DNA_REPAIR+0.321
- SPERMATOGENESIS+0.141
- MITOTIC_SPINDLE+0.081
- KRAS_SIGNALING_DN+0.029
- PI3K_AKT_MTOR_SIGNALING-0.097
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.613
- INTERFERON_GAMMA_RESPONSE-0.539
- CHOLESTEROL_HOMEOSTASIS-0.485
- IL6_JAK_STAT3_SIGNALING-0.476
- TNFA_SIGNALING_VIA_NFKB-0.475
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- NOTCH_SIGNALING-0.443
- APOPTOSIS-0.433
- INFLAMMATORY_RESPONSE-0.431
- ANGIOGENESIS-0.422
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_9PB3XH5D | medulloblastoma | — | 0.968 |
| 2 | BS_TYAYZ9ZW | medulloblastoma | — | 0.963 |
| 3 | BS_Z45HD492 | medulloblastoma | — | 0.961 |
| 4 | BS_YEB88D32 | medulloblastoma | — | 0.961 |
| 5 | BS_09Z7TC35 | medulloblastoma | — | 0.959 |
| 6 | BS_QHS3V0GP | Embryonal tumors | — | 0.956 |
| 7 | BS_3F5PR9GS | medulloblastoma | — | 0.956 |
| 8 | BS_2Z1MKS84 | medulloblastoma | — | 0.954 |
| 9 | BS_W9AT0MR7 | medulloblastoma | — | 0.952 |
| 10 | BS_FCAKKZ20 | medulloblastoma | — | 0.951 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.643 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.563 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.541 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.502 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.391 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.321 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.141 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.081 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.029 | Remibrutinib | — uncovered |